Patents by Inventor Jacob Ravn

Jacob Ravn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220204973
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 30, 2022
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • Patent number: 11267843
    Abstract: Stereodefined phosphorothioate oligonucleotides, related nucleoside monomers and methods of synthesis of both are described. The disclosed isobutyryl protected L-LNA-G monomers have following Formula 50 or 51 where R3 is independently CH2ODMTr or CH2OMMTr and R8, when present, is cyanoethyl. The monomers have improved solubility and stability characteristics, resulting in improved efficacy in oligonucleotide synthesis.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: March 8, 2022
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Jacob Ravn, Erik Daa Funder
  • Patent number: 11261209
    Abstract: The present invention relates to the synthesis of stereo-defined phosphorothioate oligonucleotides of formula I: Wherein Z, R1, R5, R6 and R9 are as defined herein. Phosphorothioate oligonucleotides are useful as therapeutics.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: March 1, 2022
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Jacob Ravn, Erik Daa Funder
  • Patent number: 11248019
    Abstract: This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine (GalNAc) compounds, in particular phosphoramidite or phosphonoamidite molecules of formula (I) with only one GalNAc moiety (formula II) and to conjugates of nucleic acid molecules with such N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine. Wherein R1 is H or C1-6alkyl; R2 is a triphenylmethyl-based hydroxyl protecting group R3 is a phosphorus-containing group, particularly a phosphoramidite or a phosphonoamidite group, and K is represented by the general formula (II).
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: February 15, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nanna Albaek, Jacob Ravn
  • Publication number: 20220031730
    Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.
    Type: Application
    Filed: June 25, 2021
    Publication date: February 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine SEWING, Søren OTTOSEN, Jacob RAVN, Lykke PEDERSEN, Souphalone LUANGSAY, Erich KOLLER, Johanna Marie WALTHER, Helene Maria GYLLING, Natascha HRUSCHKA, Susanne MOHR, Valentina D'ARIENZO
  • Publication number: 20220025376
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Patent number: 11155816
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 26, 2021
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Patent number: 11091764
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: August 17, 2021
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20210238601
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Application
    Filed: February 25, 2021
    Publication date: August 5, 2021
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Publication number: 20210162164
    Abstract: A circadian rhythm shifting method to improve future therapy effectiveness including receiving a future therapy indication, identifying a circadian cycle period that performance of the therapy is preferred, receiving a user normal circadian rhythm indication, defining a user circadian performance time range, identifying a circadian shift to change the user circadian performance time range, defining a user circadian shift protocol to cause the identified circadian shift, and providing an indication to perform an activity of the user circadian shift protocol.
    Type: Application
    Filed: February 12, 2021
    Publication date: June 3, 2021
    Applicant: Timeshifter, Inc.
    Inventors: Steven Lockley, Tony Hanna, Jacob Ravn, Mickey Beyer-Clausen, Fredric Maxik
  • Publication number: 20210017214
    Abstract: This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.
    Type: Application
    Filed: August 6, 2020
    Publication date: January 21, 2021
    Inventors: Nanna Albaek, Jacob Ravn, Christoph Rosenbohm
  • Patent number: 10815481
    Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 27, 2020
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
  • Publication number: 20200318109
    Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I 18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 8, 2020
    Inventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
  • Publication number: 20200291056
    Abstract: The present invention relates to the field of stereodefined phosphorothioate oligonucleotidess and to nucleoside monomers and methods of synthesis thereof. Herein are disclosed acyl protected L-LNA-G monomers which have improved solubility and stability characteristics, and result in improved efficacy in oligonucleotide synthesis.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 17, 2020
    Inventors: Nanna Albaek, Jacob Ravn, Erik Daa Funder
  • Publication number: 20200248186
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: September 4, 2019
    Publication date: August 6, 2020
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Publication number: 20190366032
    Abstract: A method of determining and presenting a protocol for adjusting a circadian rhythm of a user comprising receiving an indication of an intended circadian shift comprising a shift magnitude, receiving an indication of a user circadian phase, defining a user circadian shift protocol responsive to the shift magnitude and the indication of the user circadian phase, the user circadian shift protocol comprising one or more activities scheduled to be performed at a certain date and time, the activities comprising at least one of a light exposure or light avoidance activity, a chronobiotic activity, a nutritional consumption activity, a physical activity, and a rest activity. The method may further provide an indication to perform each activity on a user device.
    Type: Application
    Filed: June 5, 2019
    Publication date: December 5, 2019
    Applicant: Timeshifter, Inc.
    Inventors: Steven Lockley, Tony Hanna, Jacob Ravn, Mickey Beyer-Clausen, Fredric Maxik
  • Patent number: 10443058
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: 10385342
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 20, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: D897362
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 29, 2020
    Assignee: Timeshifter, Inc.
    Inventors: Steven Lockley, Tony Hanna, Jacob Ravn, Mickey Beyer-Clausen
  • Patent number: D943612
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: February 15, 2022
    Assignee: Timeshifter, Inc.
    Inventors: Steven Lockley, Tony Hanna, Jacob Ravn, Mickey Beyer-Clausen